{"id":1626,"date":"2020-08-26T09:35:03","date_gmt":"2020-08-26T09:35:03","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/new-stago-webinar-announcement\/"},"modified":"2021-01-08T11:12:19","modified_gmt":"2021-01-08T11:12:19","slug":"new-stago-webinar-announcement","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/new-stago-webinar-announcement\/","title":{"rendered":"New Stago Webinar announcement"},"content":{"rendered":"

How to diagnose and manage Heparin-Induced Thrombocytopenia (HIT)?<\/strong>
\nby Pr Yves Gruel – Professor of Hematology, Trousseau Hospital and University Francois Rabelais, Tours (France)<\/p>\n

Type II Heparin-Induced Thrombocytopenia (HIT) is an immune-mediated adverse effect of heparin<\/strong> treatment. Although rare, this complication can be serious and possibly life threatening<\/strong>.<\/p>\n

Approximately one third of hospitalized patients are exposed to heparins. It is therefore of great importance to know how to:<\/p>\n